Drugs / AZD5462
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06989983 | May → Jun 2025 | heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06661733 | Nov → Dec 2024 | impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05512806 | Aug → Nov 2022 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05395117 | Jun → Sep 2022 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04994106 | Jul 2021 → Sep 2022 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06299826 | Jun 2024 → Feb 2026 | heart failure | AstraZeneca | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06639087 Comparator | Sep 2024 → May 2025 | heart failure, impaired renal function disease | AstraZeneca | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5462 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06661733 ↗ |
| Route | Oral | “Participants will receive AZD5462 orally.” NCT05512806 ↗ |